Cellular adhesion and the endothelium: E-selectin, L-selectin, and pan-selectin inhibitors

Hematology/Oncology Clinics of North America

Volumn 28, Issue 2, 2014, Pages 341-354

  Telen, Marilyn J ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Adhesion; Endothelium; Integrins; Selectins; Sickle cell disease

Indexed keywords

ASELIZUMAB; BIMOSIAMOSE; E SELECTIN INHIBITOR; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; GI 270384; L SELECTIN; L SELECTIN INHIBITOR; PAN SELECTIN INHIBITOR; RIVIPANSEL; SELECTIN; SELECTIN ANTAGONIST; UNCLASSIFIED DRUG; GLYCOLIPID; GMI-1070;

CELL ADHESION; ENDOTHELIUM CELL; HUMAN; LEUKOCYTE ADHERENCE; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN STRUCTURE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SICKLE CELL ANEMIA; ANEMIA, SICKLE CELL; ARTERIAL OCCLUSIVE DISEASES; CELL COMMUNICATION; CYTOLOGY; DRUG EFFECTS; METABOLISM; PATHOPHYSIOLOGY; VASCULAR ENDOTHELIUM;

ANEMIA, SICKLE CELL; ARTERIAL OCCLUSIVE DISEASES; CELL ADHESION; CELL COMMUNICATION; E-SELECTIN; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; GLYCOLIPIDS; HUMANS; L-SELECTIN;

EID: 84896725390     PISSN: 08898588     EISSN: 15581977     Source Type: Journal    
DOI: 10.1016/j.hoc.2013.11.010     Document Type: Review

References (50)

1. Berg E., Robinson M.K., Mansson O., et al. Acarbohydrate domain common to both sialyl Lea and sialyl Lex is recognized by the endothelial cell leukocyte adhesion molecule ELAM-1. JBiol Chem 1991, 266(23):14869-14872.
2. Tedder T., Steeber D., Chen A., et al. The selectins: vascular adhesion molecules. FASEB J 1995, 9(10):866-873.
3. Smith C.W. Adhesion molecules and receptors. JAllergy Clin Immunol 2008, 121(Suppl 2):S375-S379.
4. Tedder T.F., Steeber D.A., Pizcueta P. L-selectin-deficient mice have impaired leukocyte recruitment into inflammatory sites. JExp Med 1995, 181(6):2259-2264.
5. St Hill C.A. Interactions between endothelial selectins and cancer cells regulate metastasis. Front Biosci 2011, 17:3233-3251.
6. McEver R.P., Zhu C. Rolling cell adhesion. Annu Rev Cell Dev Biol 2010, 26:363-396.
7. Chase S., Magnani J., Simon S. E-selectin ligands as mechanosensitive receptors on neutrophils in health and disease. Ann Biomed Eng 2012, 40(4):849-859.
8. Brenner B., Gulbins E., Schlottmann K., et al. L-selectin activates the Ras pathway via the tyrosine kinase p56lck. Proc Natl Acad Sci USA 1996, 24(26):15376-15381.
9. Kaul D.K., Hebbel R.P. Hypoxia/reoxygenation causes inflammatory response in transgenic sickle mice but not in normal mice. JClin Invest 2000, 106(3):411-420.
10. Chang J., Patton J.T., Sarkar A., et al. GMI-1070, a novel pan-selectin antagonist, reverses acute vascular occlusions in sickle cell mice. Blood 2010, 116(10):1779-1786.
11. Zennadi R., Chien A., Xu K., et al. Sickle red cells induce adhesion of lymphocytes and monocytes to endothelium. Blood 2008, 112(8):3474-3483.
12. Lard L.R., Mul F.P., de Haas M., et al. Neutrophil activation in sickle cell disease. JLeukoc Biol 1999, 66(3):411-415.
13. Okpala I., Daniel Y., Haynes R., et al. Relationship between the clinical manifestations of sickle cell disease and the expression of adhesion molecules on white blood cells. Eur J Haematol 2002, 69(3):135-144.
14. Faulcon L.M., Fu Z., Dulloor P., et al. Thrombospondin-1 and L-selectin are associated with silent cerebral infarct in children with sickle cell anaemia. Br J Haematol 2013, 162(3):421-424.
15. Ugochukwu C.C., Okpala I., Pantelidis P., et al. L-selectin gene polymorphisms and complications of sickle cell disease. Int J Lab Hematol 2008, 30(4):312-316.
16. Saleh A.W., Hillen H.F., Duits A.J. Levels of endothelial, neutrophil and platelet-specific factors in sickle cell anemia patients during hydroxyurea therapy. Acta Haematol 1999, 102(1):31-37.
17. Benkerrou M., Delarche C., Brahimi L., et al. Hydroxyurea corrects the dysregulated L-selectin expression and increased H(2)O(2) production of polymorphonuclear neutrophils from patients with sickle cell anemia. Blood 2002, 99(7):2297-2303.
18. Turhan A., Weiss L.A., Mohandas N., et al. Primary role for adherent leukocytes in sickle cell vascular occlusion: a new paradigm. Proc Natl Acad Sci USA 2002, 99(5):3047-3051.
19. Boateng L.A., Zennadi R., Telen M.J. Sickle red blood cell induced adhesion of neutrophils to endothelial cells and biologic correlates of leukocyte activation. Blood 2011, 118:1055.
20. Brown M.D., Wick T.M., Eckman J.R. Activation of vascular endothelial cell adhesion molecule expression by sickle blood cells. Pediatr Pathol Mol Med 2001, 20(1):47-72.
21. Sultana C., Shen Y., Rattan V., et al. Interaction of sickle erythrocytes with endothelial cells in the presence of endothelial cell conditioned medium induces oxidant stress leading to transendothelial migration of monocytes. Blood 1998, 92(10):3924-3935.
22. Shiu Y.T., Udden M.M., McIntire L.V. Perfusion with sickle erythrocytes up-regulates ICAM-1 and VCAM-1 gene expression in cultured human endothelial cells. Blood 2000, 95(10):3232-3241.
23. Belcher J.D., Marker P.H., Weber J.P., et al. Activated monocytes in sickle cell disease: potential role in the activation of vascular endothelium and vaso-occlusion. Blood 2000, 96(7):2451-2459.
24. Safaya S., Steinberg M.H., Klings E.S. Monocytes from sickle cell disease patients induce differential pulmonary endothelial gene expression via activation of NF-kappaB signaling pathway. Mol Immunol 2012, 50(1-2):117-123.
25. Hidalgo A., Chang J., Jang J.E., et al. Heterotypic interactions enabled by polarized neutrophil microdomains mediate thromboinflammatory injury. Nat Med 2009, 15(4):384-391.
26. Magnani J.L., Sarkar A., Li Y., et al. GMI-1070: a small pan-selectin antagonist that inhibits leukocyte adhesion and migration in multiple disease models invivo. Blood (ASH Annual Meeting Abstracts) 2007, 110(11):2410.
27. Xie Y.L., Seufert R., Magnani J.L., et al. Safety, tolerability and pharmacokinetics of GMI-1070, a pan-selectin inhibitor for treatment of vaso-occlusive crisis: single and multiple dose studies in healthy volunteers. Blood (ASH Annual Meeting Abstracts) 2009, 114:1526.
28. Styles L., Wun T., De Castro L.M., et al. GMI-1070, a pan-selectin inhibitor: safety and PK in a phase 1/2 study in adults with sickle cell disease. Blood (ASH Annual Meeting Abstracts) 2010, 116(21):1632.
29. Wun T., De Castro L.M., Styles L., et al. Effects of GMI-1070, a pan-selectin inhibitor, on leukocyte adhesion in sickle cell disease: results from a phase 1/2 study. ASH Annual Meeting Abstracts 2010, 116(21):262.
30. Simon S.I., Chase S., Larkin S.K., et al. Effects of selectin antagonist GMI-1070 on the activation state of leukocytes in sickle cell patients not in crisis. Blood (ASH Annual Meeting Abstracts) 2010, 116(21):2672.
31. Simon S.I., Chase S., Thackray H., et al. Inhibition of E-selectin inflammatory function by the glycomimetic GMI-1070. Blood (ASH Annual Meeting Abstracts) 2011, 118(21):851.
32. Hickey M.J., Kubes P. Intravascular immunity: the host-pathogen encounter in blood vessels. Nat Rev Immunol 2009, 9:364-375.
33. Segel G.B., Halterman M.W., Lichtman M.A. The paradox of the neutrophil's role in tissue injury. JLeukoc Biol 2011, 89(3):359-372.
34. Winkler I.G., Barbier V., Nowlan B., et al. Vascular niche E-selectin regulates hematopoietic stem cell dormancy, self renewal and chemoresistance. Nat Med 2012, 18(11):1651-1657.
35. Stark F.C., Gurnani K., Sad S., et al. Lack of functional selectin ligand interactions compromises long term tumor protection by CD8+ T cells. PloS one 2012, 7(2):e32211.
36. Läubli H., Borsig L. Selectins promote tumor metastasis. Semin Cancer Biol 2010, 20(3):169-177.
37. Luo W., Wang H., Guo C., et al. Haploinsufficiency of E-selectin ligand-1 is associated with reduced atherosclerotic plaque macrophage content while complete deficiency leads to early embryonic lethality in mice. Atherosclerosis 2012, 224(2):363-367.
38. Rossi B., Constantin G. Anti-selectin therapy for the treatment of inflammatory diseases. Inflamm Allergy Drug Targets 2008, 7(2):85-93.
39. Singbartl K., Ley K. Protection from ischemia-reperfusion induced severe acute renal failure by blocking E-selectin. Crit Care Med 2000, 28(7):2507-2514.
40. Jayle C., Milinkevitch S., Favreau F., et al. Protective role of selectin ligand inhibition in a large animal model of kidney ischemia-reperfusion injury. Kidney Int 2006, 69(10):1749-1755.
41. Kirsten A., Watz H., Kretschmar G., et al. Efficacy of the pan-selectin antagonist bimosiamose on ozone-induced airway inflammation in healthy subjects-a double blind, randomized, placebo-controlled, cross-over clinical trial. Pulm Pharmacol Ther 2011, 24(5):555-558.
42. Langer R., Wang M., Stepkowski S.M., et al. Selectin inhibitor bimosiamose prolongs survival of kidney allografts by reduction in intragraft production of cytokines and chemokines. JAm Soc Nephrol 2004, 15(11):2893-2901.
43. Nemoto T., Burne M.J., Daniels F., et al. Small molecule selectin ligand inhibition improves outcome in ischemic acute renal failure. Kidney Int 2001, 60(6):2205-2214.
44. Palma-Vargas J.M., Toledo-Pereyra L., Dean R.E., et al. Small-molecule selectin inhibitor protects against liver inflammatory response after ischemia and reperfusion. JAm Coll Surg 1997, 185(4):365-372.
45. Watz H., Bock D., Meyer M., et al. Inhaled pan-selectin antagonist bimosiamose attenuates airway inflammation in COPD. Pulm Pharmacol Ther 2013, 26(2):265-270.
46. Friedrich M., Bock D., Philipp S., et al. Pan-selectin antagonism improves psoriasis manifestation in mice and man. Arch Dermatol Res 2006, 297(8):345-351.
47. Schon M.P., Krahn T., Schon M., et al. Efomycine M, a new specific inhibitor of selectin, impairs leukocyte adhesion and alleviates cutaneous inflammation. Nat Med 2002, 8(4):366-372.
48. Panés J., Aceituno M., Gil F., et al. Efficacy of an inhibitor of adhesion molecule expression (GI270384X) in the treatment of experimental colitis. Am J Physiol Gastrointest Liver Physiol 2007, 293(4):G739-G748.
49. Seekamp A., van Griensven M., Dhondt E., et al. The effect of anti-L-selectin (aselizumab) in multiple traumatized patients-results of a phase II clinical trial. Crit Care Med 2004, 32(10):2021-2028.
50. Gaber A.O., Mulgaonkar S., Kahan B.D., et al. YSPSL (rPSGL-Ig) for improvement of early renal allograft function: a double-blind, placebo-controlled, multi-center phase IIa study. Clin Transplant 2011, 25(4):523-533.